Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the second quarter ended September 30, 2025.

Read more at globenewswire.com